11-12 September 2018 //  Lancaster Royal Hotel, London


Robert Deans

Dr Robert Deans

CTO, BlueRock Therapeutics

Dr. Deans is CTO at BlueRock Therapeutics, a regenerative medicine startup formed by Bayer and Versant Ventures to lead development of a new generation of cell therapeutics. Prior to BlueRock, Dr Deans was CSO at Rubius Therapeutics, and prior to that served as Exec VP at Athersys, responsible for the MultiStemÔ product line.  Before that Dr. Deans was VP of Research at Osiris Therapeutics, and previously an R & D Director at Baxter.  Dr. Deans has more than 25 years of experience in adult stem cell therapeutics including hematopoietic as well as mesenchymal stem cell populations and associated gene therapy approaches. He holds degrees from MIT and the University of Michigan, with postdoctoral training at UCLA.   



2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad